High-Throughput Screening for Allosteric Modulators of GPCRs
The continued evolution of our understanding of G protein-coupled receptor (GPCR) signaling has revealed new opportunities for drug discovery. Specifically, biased agonism at GPCRs and allosteric modulation of GPCRs both represent emerging areas of GPCR biology that hold promise for the development of novel GPCR-targeted therapeutics that may provide greater therapeutic efficacy and/or improved side-effect profiles. To obtain initial chemical leads, high-throughput screening (HTS) of a large compound library for the desired activity is often deployed during the early stages of a discovery program. The identification of allosteric modulators, in particular, poses significant challenges for HTS. We describe several HTS protocols designed for the identification of GPCR ligands, with a particular focus on the identification of allosteric modulators.
Key wordsG protein-coupled receptor Allosteric HTS NAM PAM SAM Calcium flux FLIPR FDSS
- 1.Filmore D (2004) It’s a GPCR world. Modern Drug Discov (Am Chem Soc) 7:24–28Google Scholar
- 7.Burford NT, Bertekap RL Jr, Banks M et al (2011) Hit identification practices for positive allosteric modulators of G protein-coupled receptors: The need for multiple-mode screening approaches in dynamic Ca2+ flux assays. Int Drug Discov 6(1):28–33Google Scholar
- 8.Sharma S, Rodriguez AL, Conn PJ et al (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett 18:4098–4101PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Rodriguez AL, Grier MD, Jones CK et al (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity an in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105–1123PubMedCentralPubMedCrossRefGoogle Scholar